Early clinical trials for adenosine deaminase–deficient severe combined immune deficiency used peripheral T cells transduced with a gammaretroviral vector, and gene-marked cells were detectable more than 10 years after infusion.32 This evidence concerns the gene ADA and Immunodeficiency.